ESMO 20th World Congress on Gastrointestinal Cancer has ended

Create Your Own Event

ESMO 20th World Congress on Gastrointestinal Cancer

14:45 PDT

Session I: Welcome, Selected Abstracts, and Opening Lecture Auditorium A, Level 0Mario Dicato • Josep Tabernero • Eric VanCutsem

14:46 PDT

Welcome and introduction Auditorium A, Level 0Mario Dicato • Josep Tabernero • Eric VanCutsem

14:50 PDT

Presentation of selected abstracts Auditorium A, Level 0

15:50 PDT

Session II: Cancer of the Pancreas and Biliary Tract Auditorium A, Level 0Teresa Macarulla • Eileen O'Reilly

15:51 PDT

Genetics in pancreatic cancer: Implications for clinical practice Auditorium A, Level 0Zsofia K. Stadler

16:10 PDT

Are we making progress in surgery of the pancreas? Auditorium A, Level 0Baki Topal

16:30 PDT

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas Auditorium A, Level 0Thierry Conroy

17:20 PDT

Presentation of selected abstracts Auditorium A, Level 0

17:50 PDT

Improving the outcome of patients with metastatic pancreatic cancer Auditorium A, Level 0Philip A. Philip

18:10 PDT

New agents/strategies on the horizon in bile duct cancer Auditorium A, Level 0Michel Ducreux

09:30 PDT

Session VI: Esophageal and Gastric Cancers Auditorium A, Level 0Michel Ducreux • Kei Muro

09:31 PDT

Management of squamous cell cancer for the esophagus Auditorium A, Level 0David H. Ilson • Florian Lordick

09:55 PDT

Locally advanced GE junction cancer Auditorium A, Level 0David Cunningham • David H. Ilson

10:20 PDT

Is FLOT the only standard in the perioperative setting for gastric cancer? Auditorium A, Level 0Andrés Cervantes

10:30 PDT

Keynote Lecture: Progress in unraveling the molecular taxonomy in oesophageal and gastric cancer Auditorium A, Level 0Patrick Tan

11:30 PDT

Session VII: Gastric Cancer Auditorium A, Level 0Fatima Carneiro • David Cunningham

11:31 PDT

Keynote Lecture: Hereditary aspects of gastric cancer Auditorium A, Level 0Fatima Carneiro

12:00 PDT

Presentation of selected abstracts Auditorium A, Level 0

12:30 PDT

Metastatic gastric cancer: Where are we with check-point inhibitors in gastric cancer? Auditorium A, Level 0Kei Muro

12:50 PDT

Metastatic gastric cancer: New targeted agents in metastatic gastric cancer Auditorium A, Level 0David H. Ilson

15:10 PDT

Session VIII: Diseases and Cancers of the Liver Auditorium A, Level 0Thomas Seufferlein • Chris Verslype

15:40 PDT

Tumor board on HCC Auditorium A, Level 0Chris Verslype • Ghassan Abou-Alfa • René Adam • Jordan D. Berlin • Christoph Deroose • Thomas Seufferlein

16:10 PDT

Presentation of selected abstract Auditorium A, Level 0

16:20 PDT

How to integrate new agents in HCC Auditorium A, Level 0Ghassan Abou-Alfa

17:10 PDT

Session IX: Expert Highlights: What is New in This disease? Auditorium A, Level 0Nadir Arber • Mario Dicato

17:11 PDT

What is new in NET in the last 12 months? Auditorium A, Level 0Marianne Pavel

17:30 PDT

What is new in GIST in the last 12 months? Auditorium A, Level 0John Zalcberg

17:50 PDT

What is new in anal cancer in the last 12 months? Auditorium A, Level 0Michel Ducreux

18:10 PDT

What is new in bile duct cancer in the last 12 months? Auditorium A, Level 0Juan W. Valle

09:30 PDT

Session XIV: Highlights Auditorium A, Level 0Mario Dicato • Eric VanCutsem

10:30 PDT

Travel Grant Award Ceremony Auditorium A, Level 0

11:05 PDT

Session XV: Multimodality Therapy for Rectal Cancer Auditorium A, Level 0Regina G.H. Beets-Tan • Karin Haustermans

12:15 PDT

Evolution and innovations in rectal cancer surgery Auditorium A, Level 0Andre D'Hoore

12:35 PDT

Presentation of selected abstract Auditorium A, Level 0

14:45 PDT

Session XVI: Molecular Biology in CRC Auditorium A, Level 0Fortunato Ciardiello • Brigetta Ma

14:46 PDT

How to approach the patient with a BRAF mutant tumor Auditorium A, Level 0Chloe Atreya

15:05 PDT

Current status and perspectives on liquid biopsies in GI cancer Auditorium A, Level 0Fortunato Ciardiello

15:25 PDT

Is circulating DNA relevant in stage II colon cancer? Auditorium A, Level 0Peter Gibbs

15:45 PDT

New insights on the molecular and immunologic classifications in CRC 8 Auditorium A, Level 0Sabine Tejpar

16:35 PDT

Presentation of selected abstract Auditorium A, Level 0

17:15 PDT

Session XVII: Immune Mechanisms and Immune Therapy in GI Cancer Auditorium A, Level 0Ali Shamseddine • Alberto Sobrero

17:16 PDT

Presentation of selected abstract Auditorium A, Level 0

17:25 PDT

Highlights of Posters at ESMO GI on colorectal cancer Auditorium A, Level 0Takayuki Yoshino

17:40 PDT

How to increase immunogenicity in MSS CRC Auditorium A, Level 0Guillem Argilés

18:00 PDT

Are we making progress with Immuno-Oncologic in pancreatic cancer? Auditorium A, Level 0Eileen O'Reilly

18:20 PDT

Session XVIII: Impact of New Evolutions in GI Oncology in Emerging Regions Auditorium A, Level 0

08:30 PDT

Session XIX: Colorectal Cancer: How to Deal with New Treatments Auditorium A, Level 0Alberto Sobrero • Josep Tabernero

09:30 PDT

Session XX: Colorectal Cancer Auditorium A, Level 0Josep Tabernero • Eric VanCutsem

09:31 PDT

Presentation of selected abstracts Auditorium A, Level 0David Cunningham

10:10 PDT

Explaining the unexplainable: CALGB vs FIRE-3 discrepant data Auditorium A, Level 0Dan Aderka

10:25 PDT

The left versus right colon cancer story: What is the truth? Auditorium A, Level 0Volker Heinemann

10:40 PDT

11:10 PDT

Session XX: Colorectal Cancer (Continued) Auditorium A, Level 0Josep Tabernero • Eric VanCutsem

11:11 PDT

How to improve on the outcome in RAS mutant tumors Auditorium A, Level 0Heinz-Josef Lenz

11:30 PDT

Presentation of selected abstracts Auditorium A, Level 0Ramon Salazar

12:10 PDT

Can we refine the selection for adjuvant treatment in stage II colon cancer? Auditorium A, Level 0Axel Grothey

12:30 PDT

Presentation of selected abstract Auditorium A, Level 0

12:40 PDT

Can we refine the selection for adjuvant treatment in stage III colon cancer? Auditorium A, Level 0Thierry André

15:10 PDT

Session XXI: From 1999 to 2018 and Beyond Auditorium A, Level 0Mario Dicato • Bernard Nordlinger

15:40 PDT

Multidisciplinary tumor board on resectable and borderline/potentially resectable liver metastases Auditorium A, Level 0Eric VanCutsem • Axel Grothey • Erika Martinelli • Bernard Nordlinger

16:10 PDT

Molecular and hereditary tumor board Auditorium A, Level 0Eric VanCutsem • Heinz-Josef Lenz • Brigetta Ma • Ramon Salazar • Zsofia K. Stadler

16:40 PDT

Session XXII: Report on Expert Consensus Discussion: The Strategy in Synchronous Oligometastatic Colorectal Cancer Auditorium A, Level 0

16:41 PDT

Presentation of outcome of expert consensus discussion Auditorium A, Level 0Mario Dicato • Josep Tabernero • Eric VanCutsem